Barclays’s Madrigal Pharmaceuticals MDGL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
– Sell
-13,900
Closed -$4.21M – 5633
2025
Q2
$4.21M Buy
+13,900
New +$4.14M ﹤0.01% 2269
2024
Q3
– Sell
-300
Closed -$84K – 5403
2024
Q2
$84K Sell
300
-8,700
-97% -$2.07M ﹤0.01% 3989
2024
Q1
$2.4M Buy
+9,000
New +$2.12M ﹤0.01% 2418
2023
Q2
– Sell
-17,600
Closed -$4.26M – 4867
2023
Q1
$4.26M Buy
+17,600
New +$4.8M ﹤0.01% 1650
2019
Q2
– Sell
-13,500
Closed -$1.69M – 7111
2019
Q1
$1.69M Sell
13,500
-28,000
-67% -$3.48M ﹤0.01% 2751
2018
Q4
$4.68M Buy
41,500
+20,500
+98% +$3.17M ﹤0.01% 1648
2018
Q3
$4.5M Buy
21,000
+16,900
+412% +$4.24M ﹤0.01% 1919
2018
Q2
$1.15M Buy
+4,100
New +$720K ﹤0.01% 3130
2015
Q4
– Sell
-471
Closed -$17K – 6322
2015
Q3
$17K Sell
471
-372
-44% -$26.8K ﹤0.01% 5543
2015
Q2
$59K Buy
843
+283
+51% +$23.7K ﹤0.01% 5041
2015
Q1
$20K Sell
560
-1,129
-67% -$96.8K ﹤0.01% 5831
2014
Q4
$118K Sell
1,689
-754
-31% -$78K ﹤0.01% 5062
2014
Q3
$257K Buy
2,443
+1,294
+113% +$180K ﹤0.01% 4517
2014
Q2
$161K Sell
1,149
-617
-35% -$90.2K ﹤0.01% 5019
2014
Q1
$247K Sell
1,766
-7,457
-81% -$1.47M ﹤0.01% 4590
2013
Q4
$1.62M Sell
9,223
-6,206
-40% -$1.14M ﹤0.01% 2884
2013
Q3
$3.24M Sell
15,429
-18,188
-54% -$3.87M ﹤0.01% 2088
2013
Q2
$5.87M Buy
+33,617
New +$8.76M 0.01% 1493

Other funds holding MDGL

Barclays's MDGL Position: Q3 2026 in Review

Barclays increased its Madrigal Pharmaceuticals (MDGL) stake by 240% in Q3 2026, buying an estimated $6.95M and bringing the position to 18,642 shares worth $9.39M. The position accounts for ﹤0.01% of the portfolio, ranked #1679.

Barclays first reported a position in MDGL in Q2 2013 and has held it in 54 quarters since. The position peaked at $25.5M in Q4 2022. 442 funds tracked by Wall St. Rank hold MDGL as of Q3 2026.

  • Barclays held 18,642 shares of Madrigal Pharmaceuticals worth $9.39M as of Q3 2026.
  • Barclays bought 13,153 Madrigal Pharmaceuticals shares in Q3 2026, an estimated $6.95M.
  • Madrigal Pharmaceuticals made up ﹤0.01% of Barclays's portfolio in Q3 2026, its #1679 holding.
  • Barclays first reported a position in Madrigal Pharmaceuticals in Q2 2013 and has held it in 54 quarters since.
  • Barclays's Madrigal Pharmaceuticals position peaked at $25.5M in Q4 2022.
  • 442 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.